↓ Skip to main content

Dove Medical Press

Article Metrics

Kinase inhibitors: a new class of antirheumatic drugs

Overview of attention for article published in Drug Design, Development and Therapy, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
6 tweeters
facebook
2 Facebook pages
f1000
1 research highlight platform

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
59 Mendeley
Title
Kinase inhibitors: a new class of antirheumatic drugs
Published in
Drug Design, Development and Therapy, September 2012
DOI 10.2147/dddt.s25426
Pubmed ID
Authors

Vasileios Kyttaris

Abstract

The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percentage of patients do not respond or lose their response over time. The autoimmune process in rheumatoid arthritis depends on activation of immune cells, which utilize intracellular kinases to respond to external stimuli such as cytokines, immune complexes, and antigens. In the past decade, small molecules targeting several kinases, such as p38 MAPK, Syk, and JAK have been developed. Several p38 MAPK inhibitors proved ineffective in treating rheumatoid arthritis. The Syk inhibitor, fostamatinib, proved superior to placebo in Phase II trials and is currently under Phase III investigation. Tofacitinib, a JAK1/3 inhibitor, was shown to be efficacious in two Phase III trials, while VX-509, a JAK3 inhibitor, showed promising results in a Phase II trial. Fostamatinib and tofacitinib were associated with increased rates of infection, elevation of liver enzymes, and neutropenia. Moreover, fostamatinib caused elevations of blood pressure and diarrhea, while tofacitinib was associated with an increase in creatinine and elevation of lipid levels.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 2%
Unknown 58 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 22%
Student > Master 12 20%
Student > Ph. D. Student 7 12%
Other 7 12%
Student > Bachelor 6 10%
Other 10 17%
Unknown 4 7%
Readers by discipline Count As %
Agricultural and Biological Sciences 18 31%
Medicine and Dentistry 17 29%
Chemistry 6 10%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Immunology and Microbiology 2 3%
Other 5 8%
Unknown 7 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2014.
All research outputs
#2,586,692
of 11,350,002 outputs
Outputs from Drug Design, Development and Therapy
#132
of 1,186 outputs
Outputs of similar age
#23,920
of 114,404 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 7 outputs
Altmetric has tracked 11,350,002 research outputs across all sources so far. Compared to these this one has done well and is in the 77th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,186 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 114,404 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them